OPDP Issues Final Guidance on Best Practices for Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements | Foley Hoag LLP

On June 27, 2023, the Food and Drug Administration’s ("FDA") Office of Prescription Drug Promotion ("OPDP") published a final guidance (the "Final Guidance") on Presenting Quantitative...

Related Keywords

,Office Of Prescription Drug Promotion ,Drug Administration ,Foley Hoag ,Final Guidance ,Prescription Drug Promotion ,Presenting Quantitative Efficacy ,Risk Information ,Promotional Labeling ,Federal Trade Commission ,